Vorasidenib Offers Hope for Slowing Low-Grade Gliomas
- Vorasidenib, the first targeted oral therapy for IDH-mutant low-grade gliomas, offers a well-tolerated way to slow tumor growth and delay more toxic treatments.
- Clinicians stress that patients must balance its benefits with uncertainties, including limited long-term data and potential side effects like GI symptoms and liver toxicity.
- They encourage patients to ask about eligibility, monitoring, how closely they match trial criteria, and the therapy’s unanswered long-term questions.
For years, patients had few medical options beyond surgery, radiation, and occasionally chemotherapy. Now, a well-tolerated daily pill offers the possibility of delaying tumor progression and postponing more toxic treatments.
Read MoreWhat We Know: A Promising Step Forward
The INDIGO trial established vorasidenib as an effective option for slowing the growth of IDH-mutant low-grade gliomas. In many cases, it helped patients delay the need for radiation or chemotherapy—treatments that can have lifelong cognitive and neurological effects.“We recognize that this agent is likely to suppress the growth and may be a means to avoid additional cytotoxic treatments such as radiotherapy or other chemotherapy,” says Dr. Braunstein.
What We Don’t Yet Know: The Unanswered Questions
“We don’t have 10-year results yet for patients who are on this trial” says Dr. Braunstein, when discussing the timing limitations of this trial.
Because the INDIGO trial enrolled patients relatively recently, researchers still cannot answer long-term questions, such as:
- Will tumors eventually progress despite treatment?
- When they do, will vorasidenib exposure change the tumor’s behavior?
- Will prognosis or treatment options change after progression?
As Dr Braunstein points out, “When this tumor does progress—which likely it ultimately will—is there a chance that having had exposure to vorasidenib will change the biology of it?
“When it does come back, will it change the prognosis or the therapies that may be available?”
He continues, “These unknowns are important to communicate to patients to set expectations so they feel informed when making the decision to take this agent.”
Personalized Medicine and the Tremendous Value of Molecular Testing Gliomas
Side Effects: What Patients Should Be Prepared For
While vorasidenib is generally well tolerated, it is not free of side effects.
“It is important to recognize that while the rates of higher-grade significant toxicity were limited, there are patients who deal with lower-grade GI toxicity” says Dr. Braunstein, when discussing balancing side effects with the benefits of treatment.
CommReported side effects include:
- Bloating
- Diarrhea
- Constipation
- Abdominal discomfort
- Nausea
- Liver toxicity (requires periodic lab monitoring)
- Fatigue
- Headache
- Dizziness
- Musculoskeletal pain
- Electrolyte changes
- Complete blood count (white blood cells, hemoglobin, platelet) changes
“It’s also not something that someone who is pregnant or planning to be pregnant should be on,” says Dr. Braunstein.
These considerations should be discussed openly with patients before initiating therapy.
What Patients Should Ask Their Doctor
- Do I have an IDH1 or IDH2 mutation confirming eligibility for vorasidenib?
- How closely does my case match the INDIGO trial population?
- What side effects should I expect, and how will they be monitored?
- How often will I need bloodwork or imaging while on treatment?
- Could vorasidenib delay or change the need for radiation or chemotherapy?
- What are the long-term unknowns with this medication?
- Is pregnancy or family planning a concern while on this therapy?
- What should I do if symptoms or side effects worsen?
Learn more about SurvivorNet's rigorous medical review process.
